Chemotherapy Effects - Pipeline Review, H1 2012

Description: Chemotherapy Effects – Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Chemotherapy Effects - Pipeline Review, H1 2012', provides an overview of the Chemotherapy Effects therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Effects, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Effects. 'Chemotherapy Effects - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Effects.
- A review of the Chemotherapy Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Effects pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Effects.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Effects pipeline depth and focus of Chemotherapy Effects therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chemotherapy Effects Therapeutic Products under Development, Key Players in Chemotherapy Effects Therapeutics, Chemotherapy Effects Pipeline Overview, Chemotherapy Effects Pipeline, Chemotherapy Effects Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Effects Overview
 Therapeutics Development
An Overview of Pipeline Products for Chemotherapy Effects
Chemotherapy Effects Therapeutics under Development by Companies
Chemotherapy Effects Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chemotherapy Effects Therapeutics – Products under Development by Companies
Chemotherapy Effects Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Chemotherapy Effects Therapeutics Development
Bristol-Myers Squibb Company
Hospira, Inc.
Kyowa Hakko Kirin Co., Ltd.
Sanofi-Aventis
Adherex Technologies Inc.
BioDelivery Sciences International, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Lentigen Corporation
A.P. Pharma, Inc.
Archimedes Pharma Limited
Aphios Corporation
Axcan Pharma Inc.
Daewoong Pharmaceutical Co., Ltd.
Maxygen, Inc.
Ono Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
CEL-SCI Corporation
Zosano Pharma, Inc.
3SBio Inc.
EpiCep Corporation
BTG International Ltd
ProMetic Life Sciences Inc.
LTT Bio-Pharma Co., Ltd.
ProStrakan Group plc
Sinobiomed, Inc.
Teikoku Pharma USA, Inc.
SymBio Pharmaceuticals Limited
Acceleron Pharma, Inc.
Neurotune AG
Med Discovery SA
Helsinn Healthcare S.A.
Wellstat Therapeutics Corporation
TroPhos SA
Tranzyme Pharma, Inc.
ARCA biopharma, Inc.
Indus Biotech Private Limited
CeNeRx BioPharma, Inc.
Orcrist Bio Inc.
Bolder Biotechnology, Inc.
Shin Nippon Biomedical Laboratories, Ltd.
Welichem Biotech Inc.
USV Limited.
Sound Pharmaceuticals, Inc.
Krenitsky Pharmaceuticals Inc.
Mechanism of Action
R&D Progress
Glutamine + Calcium + Magnesium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candesartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F511 Cream - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcium gluconate + Magnesium sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Casopitant + Ondansetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRN125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epoetin alfa + Cisplatin + Brachytherapy + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zindol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XM22 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitamin D + Calcium Carbonate + Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Glutathione + Paclitaxel - Drug Profile
Number of Products Under Development for Chemotherapy Effects, H1 2012

Products under Development for Chemotherapy Effects – Comparative Analysis, H1 2012

Number of Products under Development by Companies, H1 2012

Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2012

Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)

Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012

Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)

Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)

Bristol-Myers Squibb Company, H1 2012
Hospira, Inc., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Sanofi-Aventis, H1 2012
Adherex Technologies Inc., H1 2012
GlaxoSmithKline plc, H1 2012
Merck & Co., Inc., H1 2012
Lentigen Corporation, H1 2012
A.P. Pharma, Inc., H1 2012
Archimedes Pharma Limited, H1 2012
Aphios Corporation, H1 2012
Axcan Pharma Inc., H1 2012
Daewoong Pharmaceutical Co., Ltd., H1 2012
Maxygen, Inc., H1 2012
Ono Pharmaceutical Co., Ltd., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
CEL-SCI Corporation, H1 2012
Zosano Pharma, Inc., H1 2012
3SBio Inc., H1 2012
EpiCept Corporation, H1 2012
BTG International Ltd, H1 2012
ProMetic Life Sciences Inc., H1 2012
LTT Bio-Pharma Co., Ltd., H1 2012
ProStrakan Group plc, H1 2012
Sinobiomed, Inc., H1 2012
Teikoku Pharma USA, Inc., H1 2012
SymBio Pharmaceuticals Limited, H1 2012
Acceleron Pharma, Inc., H1 2012
Neurotube AG, H1 2012
Med Discovery SA, H1 2012
Helsinn Healthcare S.A., H1 2012
Wellstat Therapeutics Corporation, H1 2012
Trophos SA, H1 2012
Tranzyme Pharma, Inc., H1 2012
ARCA biopharma, Inc., H1 2012
Indus Biotech Private Limited, H1 2012
CeNeRx BioPharma, Inc., H1 2012
Orcrist Bio Inc., H1 2012
Bolder Biotechnology, Inc., H1 2012
Shin Nippon Biomedical Laboratories, Ltd., H1 2012
Welichem Biotech Inc., H1 2012
USV Limited., H1 2012
Sound Pharmaceuticals, Inc., H1 2012
Krenitsky Pharmaceuticals Inc., H1 2012
The GI Company, Inc., H1 2012
Almac Discovery Ltd., H1 2012
Therapure Biopharma Inc., H1 2012
Eurofarma, H1 2012
Neumedicines Inc., H1 2012
Varinel, Inc., H1 2012
Acacia Pharma Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Chemotherapy Effects Therapeutics – Drug Profile Updates
Chemotherapy Effects Therapeutics – Discontinued Products
Chemotherapy Effects Therapeutics – Discontinued Products (Contd..1)
Chemotherapy Effects Therapeutics – Dormant Products
Chemotherapy Effects Therapeutics – Dormant Products (Contd..1)
Chemotherapy Effects Therapeutics – Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Chemotherapy Effects, H1 2012
Products under Development for Chemotherapy Effects – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2021859/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chemotherapy Effects - Pipeline Review, H1 2012
Web Address: http://www.researchandmarkets.com/reports/2021859/
Office Code: SCD2LP34

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>☐</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World